RSS   Newsletter   Contact   Advertise with us

Allergan expects non-GAAP diluted EPS between $1.76 and $1.78

Staff writer ▼ | October 10, 2014
Allergan provided the following updates on earnings per share (EPS) and sales expectations based on current information.
Allergan
Very optimistic expectations   An increase of between 43 and 45 percent
Allergan expects non-GAAP diluted EPS attributable to stockholders for the third quarter of 2014 to be between $1.76 and $1.78, representing an increase of between 43 and 45 percent compared to non-GAAP diluted EPS attributable to stockholders for the third quarter of 2013.

Previous guidance provided for non-GAAP diluted EPS attributable to stockholders for the third quarter of 2014 was between $1.44 and $1.47.

Allergan expects product net sales for the third quarter of 2014 to increase in excess of 17 percent in dollars compared to product net sales for the third quarter of 2013, demonstrating a further acceleration in percentage sales growth.

Allergan expects non-GAAP diluted EPS attributable to stockholders for full year 2014 to be between $6.20 and $6.25, representing an increase of between 30 and 31 percent compared to non-GAAP diluted EPS attributable to stockholders for full year 2013.

Allergan expects product net sales for full year 2014 to increase between 14 and 15 percent in dollars compared to product net sales for full year 2013. This reflects the continued negative impact of the strengthening dollar in the fourth quarter of 2014.

Allergan expects non-GAAP diluted EPS attributable to stockholders for full year 2015 to be approximately $8.60.

Allergan expects non-GAAP diluted EPS attributable to stockholders for full year 2016 to be approximately $10.25.


 

MORE INSIDE POST